Sitthinamsuwan Panitta, Angkathunyakul Napat, Chuangsuwanich Tuenjai, Inthasorn Perapong
Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 2013 Jan;96(1):83-90.
Neuroendocrine carcinoma (NEC) is a rare entity of uterine cervical carcinoma. Most of them have a more aggressive course and worse prognosis than a common type squamous cell carcinoma. Therefore, precise diagnosis is very crucial.
To study clinicopathological correlation and immunohistochemistry of uterine cervical NEC MATERIAL AND METHOD: All primary uterine cervical carcinomas from a 51-month period were histopathologically reviewed. Suspicious NECs were retrieved and immunohistochemically studiedfor chromogranin, synaptophysin, non-specific esterase (NSE) and CD56. Clinical information including treatments and mean disease free survival time were obtainedfrom chart review
Fourteen (3.5%) cases of NEC were identified from 389primary uterine cervical carcinomas between October 1, 2002 and December 31, 2006 and classified into small cell neuroendocrine carcinoma (SNEC, 8 cases), large cell neuroendocrine carcinoma (LNEC, 3 cases), mixed SNEC and adenocarcinoma (2 cases), and mixed SNEC anid squamous cell carcinoma (1 case). All NEC presented with abnormal vaginal bleeding. The median age was 44 years (34-75 years). Exophytic mass was noted in 11 patients (78.6%). Five patients (36%) had distant metastases. All cases were immunoreactive for at least two neuroendocrine markers. Nine cases (64.3%) were positive for chromogranin, 11 (78.6%) for synaptophysin, 12 (85. 7%) for NSE, and 11 (78.6%) for CD56. CD56 was positive in eight of 11 SNEC cases. The mean disease free interval and overall survival time were 17.5 and 23.9 months, respectively
Neuroendocrine carcinoma of the cervix is rare and has poor prognosis. In addition to histopathology, panel ofimmunohistochemistry is mandatory in the diagnosis of neuroendocrine carcinoma. Varying results of immunohistochemistry may be found.
神经内分泌癌(NEC)是子宫颈癌中的一种罕见类型。与常见的鳞状细胞癌相比,大多数神经内分泌癌病程更具侵袭性,预后更差。因此,精确诊断至关重要。
研究子宫颈神经内分泌癌的临床病理相关性及免疫组化情况。
对51个月期间的所有原发性子宫颈癌进行组织病理学复查。检索出可疑的神经内分泌癌病例,并对其进行嗜铬粒蛋白、突触素、非特异性酯酶(NSE)和CD56的免疫组化研究。通过查阅病历获取包括治疗情况和平均无病生存时间在内的临床信息。
在2002年10月1日至2006年12月31日期间的389例原发性子宫颈癌中,确诊14例(3.5%)神经内分泌癌,分为小细胞神经内分泌癌(SNEC,8例)、大细胞神经内分泌癌(LNEC,3例)、混合性小细胞神经内分泌癌和腺癌(2例)以及混合性小细胞神经内分泌癌和鳞状细胞癌(1例)。所有神经内分泌癌均表现为异常阴道出血。中位年龄为44岁(34 - 75岁)。11例患者(78.6%)可见外生性肿物。5例患者(36%)发生远处转移。所有病例至少对两种神经内分泌标志物呈免疫反应。9例(64.3%)嗜铬粒蛋白阳性,11例(78.6%)突触素阳性,12例(85.7%)NSE阳性,11例(78.6%)CD56阳性。11例小细胞神经内分泌癌病例中有8例CD56阳性。平均无病间期和总生存时间分别为17.5个月和23.9个月。
子宫颈神经内分泌癌罕见,预后较差。除组织病理学外,免疫组化检测对于神经内分泌癌的诊断必不可少。免疫组化结果可能存在差异。